Article Link: Eisai Announces FDA Approval of Fycompa in Pediatric Patients as Young as 4 Years Old for the Treatment of Partial-Onset Seizures

WOODCLIFF LAKE, N.J., Sept. 28, 2018 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug Fycompa (perampanel) CIII for monotherapy and adjunctive use in…

Source: FDA New Drug Approvals